web analytics
4.6 C
Munich
Sunday, April 18, 2021

The Rise of Enzolytics Inc (OTCMKTS: ENZC) BioClonetics Merger

Enzolytics Inc (OTCMKTS: ENZC) is heating up and running northbound quickly emerging as among the most exciting stories in small caps. The stock has skyrocketed out of sub penny land and its triple zero lows attracting legions of shareholders and emerging as a volume leader in small caps.

The rise on ENZC comes as the Company merges with BioClonetics Immunotherapeutics, Inc. a biotech in the final stage of development of a parent monoclonal antibody that is being tested at the California National Primate Research Center, UCDavis for the development of a COVID-19 antibody. BioClonetics Clone 3 recombinant mAbs will be combined with the Enzolytics’ flagship compound ITV-1 which is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from major neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today. IPF has been shown to not be subject to viral resistance and is cost effective. Thereafter, PBMC based in-vitro neutralization studies will be conducted with the Enzolytics ITV-1 peptide in combination with the BioClonetics Clone 3 antibodies. Based on the results, the best combination with be tested in primate studies at the California National Primate Research Center University of California, Davis, California.

Enzolytics Inc (OTCMKTS: ENZC) is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Enzolytics is committed to creating drugs for the better health of mankind. Enzolytics, Inc. is also a 49% shareholder in IMMB BG its Bulgarian subsidiary. Enzolytics, Inc.’s flagship compound ITV-1 is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from major neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today. IPF has not shown to be subject to viral resistance and is cost effective.

BioClonetics Immunotherapeutics, Inc. is a Dallas Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for producing fully human monoclonal antibodies may be used to produce therapeutic fully human monoclonal antibodies for treating many infectious diseases including the Coronavirus.

To Find out the inside Scoop on ENZC Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

ENZC

On October 1 ENZC announced the addition of Charles Cotropia to the Company’s Board of Directors. ENZC entered into an LOI to merge with BioClonetics Immunotherapeutics, a biotech company located in Dallas Texas, on September 15, 2020. In addition, the Company announces that Harry Zhabilov, CEO of ENZC will also be joining the Board of Directors of BioClonetics. The additions to the boards of ENZC and BCLS is expected to assist each group to complete their due diligence more rapidly in order to move to definitive agreements and prepare for a smooth transition upon completion of the transaction.

The newly combined Companies plan to conduct binding studies combining the therapeutics produced by both companies to evaluate the beneficial effects and increased binding capability of the BioClonetics Clone 3 antibodies to multiple HIV isolates. Thereafter, additional PBMC based in-vitro neutralization studies will be conducted with the BioClonetics Clone 3 recombinant antibodies in combination with the Enzolytics ITV-1 peptide. Based on the results, the best combination with be tested in primate studies at the California National Primate Research Center University of California, Davis, California. In anticipation of ENZC bringing current its OTC filings the Company has made application to OTC Markets for membership. Once the Membership Application is approved by OTC Markets, the Company will begin filing its delinquent quarters. The proposed merger anticipated in the non-binding LOI will result in Charles Cotropia being appointed as CEO of the merged entity and Harry Zhabilov and Joseph Cotropia, MD, being appointed as co-CSO. Gaurav Chandra, MD, will serve as COO of the merged entity.

Charles Cotropia, CEO of BioClonetics stated: “We are looking forward to negotiating the terms of the merger for our two entities and bringing our therapies to market upon completion of clinical trials.”

We have a Monster Pick Coming. Subscribe Right Now!

Currently going parabolic on the OTCQB ENZC has skyrocketed out of sub penny land and its triple zero lows attracting legions of shareholders and emerging as a volume leader in small caps. The rise on ENZC comes as the Company merges with BioClonetics Immunotherapeutics, Inc. a biotech in the final stage of development of a parent monoclonal antibody that is being tested at the California National Primate Research Center, UCDavis for the development of a COVID-19 antibody. BioClonetics Clone 3 recombinant mAbs will be combined with the Enzolytics’ flagship compound ITV-1 which is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from major neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today. IPF has been shown to not be subject to viral resistance and is cost effective. Thereafter, PBMC based in-vitro neutralization studies will be conducted with the Enzolytics ITV-1 peptide in combination with the BioClonetics Clone 3 antibodies. Based on the results, the best combination with be tested in primate studies at the California National Primate Research Center University of California, Davis, California. We will be updating on ENZC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ENZC.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in ENZC either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.